CJC-1295 No DAC Research Peptide

Peptora Compound Research Library

CJC-1295 No DAC Research Peptide Overview

CJC-1295 No DAC Research Peptide is a name widely used for Modified GRF (1-29), a synthetic 29-amino-acid analogue related to the biologically active N-terminal region of growth hormone-releasing hormone (GHRH). Research surrounding this peptide family examines GHRH-receptor signalling, pituitary growth-hormone release and the structural changes used to improve resistance to peptide degradation.

Research Library Commonly Studied Peptides Testing & COAs Research Peptides

Compound overview

What Is CJC-1295 No DAC Research Peptide?

CJC-1295 No DAC is commonly used as a commercial name for Modified GRF (1-29), also written Mod GRF 1-29.

The peptide is based on the first 29 amino acids of growth hormone-releasing hormone, historically also called growth hormone-releasing factor or GRF. This N-terminal region contains the biological activity required for interaction with the GHRH receptor.

Modified GRF (1-29) introduces amino-acid substitutions into this 29-residue framework to increase resistance to enzymatic degradation while retaining GHRH-receptor activity.

The Naming Distinction Matters

Modified GRF (1-29): a modified 29-amino-acid GHRH-related peptide lacking an albumin-binding Drug Affinity Complex.

CJC-1295 No DAC: the name widely used in the research-material market for Modified GRF (1-29).

CJC-1295 with DAC: a related but chemically distinct albumin-binding analogue developed for prolonged circulation.

These names should not be treated as interchangeable without specifying whether the DAC modification is present.

Structural research

CJC-1295 No DAC and Modified GRF (1-29)

The Modified GRF (1-29) backbone commonly associated with CJC-1295 No DAC contains four substitutions relative to native GRF/GHRH(1-29).

Position 2

A D-alanine substitution is used at position 2, a region important to resistance against rapid enzymatic cleavage.

Position 8

Glutamine is incorporated at position 8 within the modified 29-residue sequence.

Position 15

Alanine is incorporated at position 15 as part of the tetrasubstituted GRF structure.

Position 27

Leucine is incorporated at position 27 within Modified GRF (1-29).

29 Residues

The peptide retains the 29-residue framework derived from the active N-terminal region of GHRH.

No DAC

No Albumin-Binding Group

The No-DAC material lacks the Drug Affinity Complex used in long-acting CJC-1295.

GHRH biology

CJC-1295 No DAC Research Peptide and GHRH

Growth hormone-releasing hormone is a hypothalamic signalling peptide involved in regulation of growth-hormone secretion from anterior-pituitary somatotroph cells.

The first 29 amino acids of GHRH contain the receptor-activating portion of the molecule. This observation led to extensive research involving GHRH(1-29) and structurally modified analogues.

Hypothalamic Signal

Native GHRH functions as part of the physiological signalling network controlling pituitary growth-hormone release.

GHRH Receptor

GHRH-related peptides are studied for interaction with the GHRH receptor on pituitary somatotroph cells.

29-Residue Region

The N-terminal 1–29 region retains the receptor-related biological activity that made it a focus of analogue development.

Analogue Research

Structural modifications have been investigated to alter stability while maintaining receptor signalling.

Enzymatic stability

Why Modified GRF (1-29) Uses Amino-Acid Substitutions

Native GHRH-derived fragments can be rapidly degraded by circulating peptidases. One important pathway involves dipeptidyl peptidase IV, also known as DPP-4.

Modification near the N-terminus can reduce susceptibility to this cleavage pathway. Modified GRF (1-29) therefore provides a useful research model for examining how sequence changes influence peptide stability and receptor activity.

Important distinction: improved resistance to enzymatic degradation does not mean that the No-DAC material has the multi-day circulation profile reported for albumin-binding CJC-1295 with DAC.

For broader discussion of degradation and handling variables, see Understanding Peptide Stability.

DAC comparison

CJC-1295 No DAC vs CJC-1295 With DAC

The presence or absence of the Drug Affinity Complex is one of the most important distinctions when interpreting CJC-1295 literature.

Feature	CJC-1295 No DAC / Modified GRF (1-29)	CJC-1295 With DAC
Core peptide	Modified GHRH/GRF(1-29) analogue	Modified GHRH-related peptide incorporated into an albumin-binding design
Drug Affinity Complex	Absent	Present
Albumin binding	No DAC-mediated albumin conjugation	Designed for covalent association with circulating albumin
Research profile	Shorter-duration GHRH-receptor research model	Designed for substantially prolonged exposure
Human CJC-1295 PK literature	Should not be inferred from DAC studies	Human pharmacokinetic studies reported prolonged GH and IGF-1 responses

Evidence rule: when a study says “CJC-1295,” researchers should determine which molecular form was actually investigated before applying its findings.

Receptor signalling

CJC-1295 No DAC and GHRH-Receptor Research

The GHRH receptor is a G-protein-coupled receptor expressed prominently on pituitary somatotroph cells. Activation of this receptor initiates intracellular signalling associated with growth-hormone secretion.

Modified GHRH analogues are therefore useful experimental tools for studying the relationship between peptide structure, receptor activation and downstream endocrine signalling.

Receptor Activation Is Not the Same as Clinical Benefit

Demonstrating that a peptide interacts with a receptor or influences a hormone-related pathway provides mechanistic information.

It does not independently establish a clinical outcome, treatment indication, long-term safety profile or appropriate use in humans.

GH and IGF-1 research

Growth-Hormone and IGF-1 Research Context

GHRH analogues are commonly studied through growth-hormone and downstream insulin-like growth factor 1 signalling.

Human studies of the long-acting DAC-containing CJC-1295 molecule reported prolonged increases in circulating GH and IGF-1. Those findings are useful for understanding the DAC platform but should not be presented as direct pharmacokinetic evidence for CJC-1295 No DAC.

For the No-DAC material, the more defensible scientific framework is the broader literature involving GHRH(1-29), Modified GRF analogues, receptor activation and peptide stability.

Why the Literature Must Be Separated

The DAC modification changes how the molecule interacts with serum albumin and therefore substantially changes its pharmacokinetic behaviour.

A result obtained with an albumin-binding molecule cannot automatically be transferred to an otherwise related peptide that lacks that modification.

Related compound

CJC-1295 No DAC and Ipamorelin Research

CJC-1295 No DAC and ipamorelin are frequently discussed together, but they belong to different peptide signalling systems.

Modified GRF (1-29) is studied through the GHRH receptor. Ipamorelin is a growth-hormone secretagogue investigated through the ghrelin/GHS-R1a receptor.

The planned Ipamorelin Research Peptide Overview examines that compound independently so that evidence for the two receptor systems remains clearly separated.

Research principle: two compounds being investigated together does not mean findings for one compound automatically apply to the other or to a combined research material.

Related GHRH analogue

CJC-1295 No DAC, Sermorelin and GHRH(1-29)

Sermorelin provides another useful comparison because it is based on GHRH(1-29) without the same four substitutions associated with Modified GRF (1-29).

Comparing these compounds helps illustrate how small changes in amino-acid sequence can influence susceptibility to enzymatic degradation while preserving a common receptor-related research framework.

Material	General Structure	Research Distinction
Native GHRH	Endogenous hypothalamic peptide	Physiological reference molecule
GHRH(1-29) / Sermorelin	N-terminal 29-residue GHRH fragment	Retains GHRH-receptor activity but remains susceptible to rapid degradation
Modified GRF (1-29)	Tetrasubstituted 29-residue analogue	Designed for increased resistance to enzymatic degradation
CJC-1295 with DAC	Modified GHRH-related structure with albumin-binding modification	Designed for markedly prolonged exposure

Our planned Sermorelin Research Peptide Overview will examine GHRH(1-29) separately.

Evidence interpretation

Understanding CJC-1295 No DAC Research Evidence

The terminology surrounding CJC-1295 creates an unusual evidence problem: studies using related GHRH analogues are sometimes discussed as though they all involve the same molecule.

✓ Identify whether DAC is present.

✓ Distinguish Modified GRF from native GHRH.

✓ Separate receptor data from clinical outcomes.

✓ Do not transfer DAC pharmacokinetics to No DAC.

✓ Distinguish CJC-related research from ipamorelin research.

✓ Verify the actual molecular material studied.

Analytical documentation

CJC-1295 No DAC Research Peptide: Identity and Batch Testing

The naming ambiguity surrounding CJC-1295 makes analytical identity particularly important for laboratory research.

A label saying only “CJC-1295” does not by itself establish whether a material contains a DAC modification. Researchers should evaluate the stated compound identity together with batch-specific analytical documentation.

✓ Confirm whether the material is No DAC.

✓ Confirm the stated peptide identity.

✓ Match documentation to the applicable batch.

✓ Review purity where reported.

✓ Review identity testing where reported.

✓ Review measured content where reported.

✓ Identify the analytical methods used.

✓ Review additional tests only where documented.

For the analytical framework, read Peptide Purity & Certificates of Analysis (COAs) Explained and Peptora's Testing & COAs.

Research network

Continue Exploring CJC-1295 No DAC Research

This overview connects CJC-1295 No DAC with Peptora's broader educational network covering related compounds, peptide stability, analytical documentation and research-material identity.

Related Peptide Research Resources

Continue into related compound overviews and foundational research education.

Ipamorelin Research Peptide Overview → Sermorelin Research Peptide Overview → Tesamorelin Research Peptide Overview → Commonly Studied Research Peptides in Canada → What Are Research Peptides? → Understanding Peptide Stability → Peptide Purity & COAs Explained → Complete Research Library →

CJC-1295 No DAC FAQ

CJC-1295 No DAC Research Peptide: Frequently Asked Questions

Common research questions about CJC-1295 No DAC, Modified GRF (1-29), GHRH signalling and the Drug Affinity Complex distinction.

What is CJC-1295 No DAC?

CJC-1295 No DAC is a name widely used for Modified GRF (1-29), a synthetic 29-amino-acid GHRH-related peptide containing four substitutions and lacking the albumin-binding Drug Affinity Complex.

Is CJC-1295 No DAC the same as Modified GRF (1-29)?

The names are widely used interchangeably in the research-material market. Modified GRF (1-29) more directly describes the tetrasubstituted 29-residue GHRH-related peptide lacking DAC.

What does No DAC mean?

No DAC means that the material does not contain the Drug Affinity Complex albumin-binding modification associated with long-acting CJC-1295.

Is CJC-1295 No DAC the same as CJC-1295 with DAC?

No. The DAC-containing molecule incorporates an albumin-binding modification that substantially changes its pharmacokinetic behaviour. Findings involving that form should not automatically be attributed to the No-DAC material.

What receptor is associated with Modified GRF (1-29)?

Modified GRF (1-29) is a GHRH-related analogue studied through the growth hormone-releasing hormone receptor.

How is CJC-1295 No DAC different from ipamorelin?

They involve different receptor systems. Modified GRF (1-29) is studied through the GHRH receptor, while ipamorelin is a growth-hormone secretagogue associated with the ghrelin/GHS-R1a receptor.

Can CJC-1295 with DAC human studies be applied directly to No DAC?

No. The DAC modification produces albumin binding and substantially alters exposure. Human pharmacokinetic findings from DAC-containing CJC-1295 should therefore not be presented as direct evidence for the No-DAC material.

Does published research verify a specific CJC-1295 No DAC batch?

No. A specific laboratory batch must be evaluated using the analytical documentation associated with that batch.

Research use only

CJC-1295 No DAC for Controlled Laboratory Research

This overview provides educational information about Modified GRF (1-29), CJC-1295 terminology and GHRH-related experimental research. Findings involving native GHRH, other GHRH analogues or DAC-containing CJC-1295 should not automatically be interpreted as findings involving CJC-1295 No DAC.

Peptora Peptide Labs research products are intended solely for controlled non-clinical laboratory research. They are not intended for human or veterinary consumption, compounding or clinical use. Nothing on this page provides medical advice, dosing or administration guidance, or representations concerning diagnosis, treatment, cure or prevention of disease.